| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/09/2005 | US20050124640 Pyrimidine derivatives useful as inhibitors of PKC-theta |
| 06/09/2005 | US20050124638 Benzimidazoles and analogs thereof as antivirals |
| 06/09/2005 | US20050124637 For example, {4-[2-(4-Amino-cyclohexylamino)-9-phenyl-9H-purin-6-ylamino]-phenyl}-piperidin-1-yl-methanone; inhibit the activity of one or more protein kinases and are, therefore, expected to be useful in the treatment of kinase-associated diseases |
| 06/09/2005 | US20050124636 Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| 06/09/2005 | US20050124634 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 06/09/2005 | US20050124633 For the treatment of myosin heavy chain-mediated diseases, and in particular, heart failure |
| 06/09/2005 | US20050124632 Use of aminobenzenesulfonic acid derivative or a salt, hydrate, or solvate thereof; treatment of heart failure or arrhythmia in diabetic ischemic heart disease |
| 06/09/2005 | US20050124631 For example, 2-amino-7-chloro-6-hydroxy-4-methylbenzothiazole; compounds that prevent the formation of polyglutamine containing protein aggregates; treatment of spinal and bulbar muscular atrophy, dentatorubal pallidoluysian atrophy, spinocerebellar ataxia, Alzheimers disease |
| 06/09/2005 | US20050124628 Quinoline and aza indole compounds having pharmacological activity, for example, 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; use in the treatment of CNS and other disorders |
| 06/09/2005 | US20050124627 Use as excitatory amino acid antagonists for combating neurodegenerative and cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, or psychoses; for example, 3-[4-(3,4-methylenedioxybenzyl)piperidino]-N-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propionamide |
| 06/09/2005 | US20050124626 Novel compounds |
| 06/09/2005 | US20050124624 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases |
| 06/09/2005 | US20050124623 For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS |
| 06/09/2005 | US20050124622 Compounds and methods for the treatment of pain |
| 06/09/2005 | US20050124621 Novel inhibitors of kinases |
| 06/09/2005 | US20050124620 Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's |
| 06/09/2005 | US20050124619 Medical devices employing triazine compounds and compositions thereof |
| 06/09/2005 | US20050124618 Methods of modulating angiogenesis and cancer cell proliferation |
| 06/09/2005 | US20050124616 prophylaxis and treatment of herpes viral infections; e.g. N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-c]pyrimidin-7-amine |
| 06/09/2005 | US20050124615 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 06/09/2005 | US20050124614 E. g., 3,5-bis-trifluoromethylphenyl)-4-[(furan-2-ylmethyl)-aminocarbonyl]-2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline;anticarcinogenic agents; antitumor agents; antiproliferative agents; activators of the caspase cascades; enzyme inhibitors used in combination with radiation or chemotherapy |
| 06/09/2005 | US20050124613 Benzoxazine derivatives and uses thereof |
| 06/09/2005 | US20050124611 Such as N-[4-[[4-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-oxo-6-(trifluoromethyl)-3-quinolinyl]thio]phenyl]-4-morpholineacetamide; potassium channel modulators |
| 06/09/2005 | US20050124610 cyclin dependent kinase (CDK) inhibitors useful in treating or ameliorating a CDK mediated disorder consisting of cervical adenocarcinoma, colon carcinoma and malignant melanoma |
| 06/09/2005 | US20050124609 Orally administering to a patient a methylol transfer agent; e.g., an oral dose of about 100-1000 mg. of taurolidine, taurultam or mixtures; ulcerative colitis; Crohn's disease; reduces side effects when administered with other drugs; synergistic; bactericides; endotoxins; antiinflammatory agents |
| 06/09/2005 | US20050124608 taurolidine or taurultam; inhibiting growth of a tumor cell |
| 06/09/2005 | US20050124607 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists |
| 06/09/2005 | US20050124606 Novel benzothiazine and benzothiadiazine derivatives method for preparing same and pharmaceutical compositions containing same |
| 06/09/2005 | US20050124605 E.g., substituted 2,3,5,10b-tetraaza-benzo[e]azulen-6-yl)-acetic acids, 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl)-(4,6-dimethoxy-pyrimidin-2-yloxy)-acetic acids and 2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-ylmethyl}-benzoates; treating circulatory, inflammatory, and proliferative disorders |
| 06/09/2005 | US20050124603 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 06/09/2005 | US20050124602 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; treating a thromboembolic disorder such as deep vein thrombosis or pulmonary embolism |
| 06/09/2005 | US20050124601 Methods for the treatment of bipolar disorder using carbamazepine |
| 06/09/2005 | US20050124597 Novel guanidinyl derivatives |
| 06/09/2005 | US20050124595 Administering an indole diterpene from the fungus strain of Chaunopycnis pustulata to relieve ocular pressure and provide neuroprotection; potent potassium channel and maxi-K channel blockers; side effect reduction; nonneurotoxic; antiedema agents |
| 06/09/2005 | US20050124594 Prophylactic treatment of eyes as having high risk of developing choroidal neovascularisation in macular degerneration by injecting an antiinflammatory steroid, e.g., triamcinolone acetonide, into the vitreous; occult and classic neovascularisation; mixture with antibiotic or angiogenesis inhibitors |
| 06/09/2005 | US20050124593 Administering a nitroxide-containing compound, e.g., Tempol, to treat and alleviate inflammatory skin disorders, e.g., rosacea, atopic dermatitis, contact dermatitis, a drug eruption, psoriasis, seborrheic dermatitis, a connective tissue disease, an autoimmune disorders, urticaria or hives, or infection |
| 06/09/2005 | US20050124592 Administering tibolone to female patients to treat estrogen-deficiency related, climacteric complaints exhibited while the female patients are being treated with a drug to prevent the biosynthesis of endogenous estrogen; aromatase inhibitors to prevent bone loss; reduced side efffcts for cancer patients |
| 06/09/2005 | US20050124591 Use of vitamin Ds to treat kidney disease |
| 06/09/2005 | US20050124590 Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells |
| 06/09/2005 | US20050124589 New use, pharmaceutical preparations as well as a process for their production |
| 06/09/2005 | US20050124586 Alpha-substituted arylalkyl phosphonate derivatives |
| 06/09/2005 | US20050124585 Which contain phosphoramidate linkages; for retroviral or hepadnaviral therapy; for treatment of HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability |
| 06/09/2005 | US20050124584 Prodrugs of phosphonate nucleotide analogues |
| 06/09/2005 | US20050124583 Prodrugs of phosphonate nucleotide analogues |
| 06/09/2005 | US20050124582 2-amino-6-substituted-9-[(2-hydroxymethyl or phosphatomethyl)cyclopropylidenemethyl]purines; herpes viruses, cytomegalo virus, Epstein-Barr virus, HIV |
| 06/09/2005 | US20050124581 Alpha-substituted heteroarylalkyl phosphonate derivatives |
| 06/09/2005 | US20050124580 Bis[(dihydroxyborylphenyl)carbonyloxy]benzenes may be synergistically combined with beta-lactam antibiotics to treat beta-lactam antibiotic resistant bacterial infections |
| 06/09/2005 | US20050124579 or microbiocidal treatment of surfaces, e. g., m-octyloxybenzyl alcohol; antiseptics; preservatives; deodorization and disinfection of the skin, mucosae and hair; finishes fortextile fiber, plastics, paper, nonwovens, wood leather;washing/cleaning compounds; cosmetics; printing thickeners of starch |
| 06/09/2005 | US20050124578 Aqueous compositions containing metronidazole |
| 06/09/2005 | US20050124575 Remedies |
| 06/09/2005 | US20050124574 Purine derivatives |
| 06/09/2005 | US20050124562 Using Dna polymerase inhibitor as bactericide |
| 06/09/2005 | US20050124561 Administering fungicide for mucous membrane; asthma therapy |
| 06/09/2005 | US20050124559 Antimicrobial agent |
| 06/09/2005 | US20050124558 Controlling particle size; bioavailability |
| 06/09/2005 | US20050124557 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 06/09/2005 | US20050124554 Spermidine derivatives for the treatment of chronic neurodegenerative diseases |
| 06/09/2005 | US20050124552 Use of glutathione synthesis stimulating compounds in reducing insulin resistance |
| 06/09/2005 | US20050124537 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/09/2005 | US20050124536 Antifungal combination use |
| 06/09/2005 | US20050124534 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring |
| 06/09/2005 | US20050124533 Central nervous system disorders; adjust permeability of brain-bnlood barrier |
| 06/09/2005 | US20050124532 Using nucleoside, or prodrug thereof |
| 06/09/2005 | US20050124531 Angiogenesis inhibitors; prevent cancer cells metastasis; antiarthritic agents; skin disorders; retinopathy; atherosclerosis |
| 06/09/2005 | US20050124069 Transfection reagents |
| 06/09/2005 | US20050124039 Mixing cationic lipid with a polynucleotide, coding for antigenic determinant, thereby forming a cationic lipid-polynucleotide complex; administering complex to animal for eliciting an immune response |
| 06/09/2005 | US20050124036 Method for producing recombinant proteins in micro-organisms |
| 06/09/2005 | US20050123999 Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods |
| 06/09/2005 | US20050123983 Methods and compositions for overcoming resistance to biologic and chemotherapy |
| 06/09/2005 | US20050123910 Nucleotide sequences coding prolyl oligopeptidase (DPP10) for use in identifying modulator which prevent and treat allergies, asthma, skin and inflammatory diseases |
| 06/09/2005 | US20050123906 For treating HIV infections; drug screening |
| 06/09/2005 | US20050123902 Human papillomavirus inhibitors |
| 06/09/2005 | US20050123897 Controlling flux of penetrants across adaptable, semipermeable porous barrier by enlarging applied dose per area; drug delivery kits, patches |
| 06/09/2005 | US20050123775 Used to form a functionalized coating on substrate; array of nucleic acids may be covalently attached to substrate to make high density arrays to nucleic acids immobilized on substrate which may be used in high volume nucleic acid hybridization |
| 06/09/2005 | US20050123671 Incorporating trehalose into an edible aqueous system containing alpha glucosyl hesperidin or catechin or both followed by sterilization |
| 06/09/2005 | US20050123662 Soybean saponin-containing material and process for producing the same |
| 06/09/2005 | US20050123636 Total coumarins include six active compounds, which have been identified as osthal, xanthotoxol xanthotoxin, isopimpinellin, bergapten, imperatorine; little side-effect |
| 06/09/2005 | US20050123633 Obtained by fermenting soybean germ, which is used as raw material, with koji mold, thus breaking down proteins, then hydrolyzing, extracting and concentrating using solvent to produce an isoflavone aglycone concentrate |
| 06/09/2005 | US20050123628 Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| 06/09/2005 | US20050123627 an alkalizing agent; and multiparticulates containing about 20% to 75% azithromycin, and, about 25% to 80% of a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate and a poloxamer |
| 06/09/2005 | US20050123623 Pharmaceutical compositions and their use in the treatment of neoplastic disease |
| 06/09/2005 | US20050123621 Silver coatings and methods of manufacture |
| 06/09/2005 | US20050123620 Compositions and methods for topical treatment of skin infection |
| 06/09/2005 | US20050123616 Azithromycin multiparticulate dosage forms by liquid-based processes |
| 06/09/2005 | US20050123615 Controlled release dosage forms of azithromycin |
| 06/09/2005 | US20050123612 Ribavirin granulate for producing coated tablets |
| 06/09/2005 | US20050123607 Pharmaceutical formulation of valaciclovir |
| 06/09/2005 | US20050123606 Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| 06/09/2005 | US20050123605 Anticancer agents; prevent forming blood vessels; removal blockage |
| 06/09/2005 | US20050123604 Comprise 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid; cyclooxygenase-2 dependent disorder |
| 06/09/2005 | US20050123603 Oral delivery vehicle; food products |
| 06/09/2005 | US20050123597 Releasable linkage and compositions containing same |
| 06/09/2005 | US20050123593 Chondroitin sulfate, keratinsulphate, heparin, heparin sulfate and dermatan sulfate encapsulated in a bilayer forming dipalmitoylphosphatidylcholine phospholipid; dosage; osteoarthritis |
| 06/09/2005 | US20050123585 Two or more minerals: zinc, copper, manganese, tin or salt of zinc, copper, manganese for treating oral cavity plaque, oral cavity tartar, periodontal disease, gingivitis, breath odor of domestic animals |
| 06/09/2005 | US20050123580 Method of treating atherosclerosis and hypercholesterolemia |
| 06/09/2005 | US20050123577 Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs |
| 06/09/2005 | US20050123576 Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| 06/09/2005 | US20050123575 Heating, cooling, reheating and recooling a mixture containing hard fat while stirring; cosmetics, cosmeceutical, pharmaceutical; second temperature is lower than the congelation temperature of the mixture; hard fat is a mixture of triester of glycerin with caprylic, capric and stearic acids |
| 06/09/2005 | US20050123570 Tyrosine, modified or unmodified allergen, and 3-deactylated monophosphoryl lipid A; treating a patient susceptible to allergy |
| 06/09/2005 | US20050123566 Immunomodulatory compounds and methods of use thereof |